Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure hope? roxadustat tested for anemia and kidney disease

NCT ID NCT07268807

Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether roxadustat, a drug for anemia in chronic kidney disease, can also help people with heart failure. Researchers will review medical records of 200 patients who took roxadustat for at least a year. They will check heart function, symptoms, and major events like hospitalizations or death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
roxadustat
What this could lead to
If successful, this could show that roxadustat helps manage heart failure and anemia in people with chronic kidney disease, potentially improving their heart function and quality of life.
What could go wrong
This is a small, retrospective study that looks back at past data, not a controlled trial. Results may not prove cause and effect, and the drug may not work as hoped in larger, future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Heart Failure Patients with Anaemia and Moderate-to-Severe Chronic Kidney Disease

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * aged 18-85 years, regardless of gender; * fulfilled the diagnostic criteria for heart failure and chronic kidney disease; * haemoglobin level \<130 g/L for men or \<120 g/L for women at baseline; * had regularly received Roxadustat for over one year; * possessed complete clinical data, including information from pre-specified time points. Exclusion Criteria: * comorbid myelodysplastic syndromes, multiple myeloma, hereditary hematologic diseases (e.g., thalassemia, sickle cell anaemia, pure red cell aplasia), hemosiderosis, hemochromatosis, or other disorders confirmed to cause anaemia due to erythrocyte destruction and/or abnormal hematopoietic function; * haemoglobin level ≤45 g/L on two or more blood tests, a history of major bleeding within one year, or a history of anaemia corrected by blood transfusion; * bilateral nephrectomy, kidney transplantation within ≤6 months, or congenital kidney diseases (e.g., polycystic kidney disease); * hypertrophic obstructive cardiomyopathy or congenital heart disease with right-to-left shunt; * comorbid malignancy with an investigator-assessed life expectancy of less than 12 months; * pregnancy or lactation; * known allergy to the study drug (active ingredient or excipients); * participation in a drug clinical trial within one year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia CKD Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongda hospital Southeast University

    Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.